

Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow

Les Pensières
Fondation Mérieux conference center
Veyrier-du-Lac - France

19-21 January 2015

Steering Committee:

- David Bloom
- Jacques Louis
- Valentina Picot
- Stanley Plotkin
- Michael Watson

*Cindy Grasso meeting coordinator

des racines pour la vie • roots for life



Background

Vaccines prevent around five premature deaths every minute and with the right conditions for access, effectiveness, innovation, and sustainability, the opportunity to increase the number of lives saved is substantial. Given the massive contribution of vaccination to the public, good international aid and philanthropic donors have injected immense sums of money to make this happen. GAVI will spend over 7 billion dollars and the global polio eradication program over 5 million dollars between 2010 and 2015. Whilst this has led to many exceptional achievements, success should not prevent continuous examination of whether we are fully optimising the huge untapped potential of today's vaccines without damaging the benefit that future vaccination innovation can bring.

Vaccination is a very complex ecosystem and like natural ecosystems, it can be fragile. For example in the 1990s demands for high volumes and low prices, rising quality and regulatory standards, new production technologies and standards, the threat of litigation in the USA, and the royalty costs of licensing IP from Biotech and academia led to dramatic contractions within the sector, widespread closure of manufacturers, and shortages of a number of essential vaccines.

Today's vaccine ecosystem is defined by the pursuit of polio eradication, the drive to get as many of the new vaccines to as many people as possible and the R&D pursuit of vaccines against immunologically challenging diseases such as HIV, Malaria, TB, Dengue, RSV, HSV, Chlamydia and others. This era is also characterised by the emergence of major private donors and government subsidies. These donors and their agencies aim to extend global access to all vaccines through «push and pull» innovation in vaccines and vaccines systems. To achieve this they implement “market-shaping” aimed at incentivising increased volumes, lower prices and new producers of high volume, low-cost versions of existing vaccines.

This meeting aims to take stock of how healthy today's vaccination ecosystem is and its ability to reliably and sustainably supply high quality vaccines whilst maintaining investment in the innovation that we need for tomorrow.



Monday 19 January 2015

17:30 - 18:30	Registration	
18:30 - 18:50	Welcome address	Fondation Mérieux
18:50 - 19:30	Key-note address 1: Valuing vaccination	David Bloom
19:40	Welcome dinner	

Tuesday 20 January 2015

8:30 - 9:10	Key-note address 2: Shaping immunization programmes in the current decade	Thomas Cherian
-------------	--	----------------

Session 1

Today's vaccination ecosystem status-
Coverage, supply and innovation
Chair: Bruce Gellin

09:15- 09:35	Global vaccination coverage and gaps	Marta Gacic-Dobo
09:35- 09:50	Discussion	
09:50 - 10:10	Global vaccine demand, supply and outlook	Heather Deehan
10:10 - 10:25	Discussion	
10:25 - 11:05	Coffee break	
11:05 - 11:20	Global vaccines R&D health past, present and future	Stanley Plotkin
11:20 - 11:45	Discussion	
11:45 - 12:00	The costs and effectiveness of large pre - licensure phase III clinical trials: time for a new paradigm?	Steve Black
12:00- 12:15	Discussion	

Scientific programme

Session 2

Today's vaccination ecosystem status – Market-shaping principles, practice, impact and lessons learned

Chair: David Bloom

12:15 - 12:35	The GAVI perspective	Aurelia Ngyuyen
12:35 - 12:50	Discussion	
12:50 - 14:15	Lunch	
14:15 - 14:35	Perspectives on vaccine market dynamics for lower income countries	Greg Widmyer
14:35 - 14:50	Discussion	
14:50 - 15:10	UNITAID/CHAI/WHO perspective	Brenda Waning
15:10 - 15:25	Discussion	
15:25 - 15:45	A producer's perspective 1	Michael Watson
15:45 - 16:00	Discussion	
16:00 - 16:20	Coffee break	
16:20 - 16:40	A producer's perspective 2	Suresh Jadhav
16:40 - 16:55	Discussion	
16:55 - 17:15	A donor's perspective on acces to medicine, with specific reference to vaccines	Ross Leach and James Droop
17:15 - 17:30	Discussion	

Session 3

Healthy and unhealthy markets

Chair: David Salisbury

17:30- 17:50	What is a healthy market, why does it happen and when is it desirable?	Martin S. Gaynor
17:50 - 18:05	Discussion	
18:05 - 18:25	What is market failure, why does it happen and how can it be fixed?	Awi Federgruen
18:25 - 18:40	Discussion	
19:30	Dinner	



Scientific programme

Wednesday 21 January 2015

Session 3 (continued)

Healthy and unhealthy markets (continued)

Chair: David Salisbury

08:30 - 08:50	A market failure case study - Antibiotics	Anthony So
08:50 - 09:05	Discussion	
09:05 - 09:25	A market failure case study – Snake anti-venoms	Jennifer Cohn and Julien Potet
09:25 - 09:40	Discussion	
09:40 - 10:00	The global anti-venom neglect: an overview	Robert Harrison
10:00 - 10:15	Discussion and wrap-up	
10:15 - 10:45	Coffee break	
10h45-11h30	Preparing the Workshops	
11:30 - 13:00	Workshops	
	Workshop 1: What are the drivers and barriers to a sustainable vaccination ecosystem?	Kaitlin Christenson
	Workshop 2: What are the metrics of vaccination ecosystem health?	Michael Watson
	Workshop 3: What should we add, remove, increase or reduce to keep the vaccination ecosystem healthy?	Henry Miller
13:00 - 14:30	Lunch - In workshops groups	
14:30 - 14:50	Feedback from workshop 1	
14:50 - 15:10	Feedback from workshop 2	
15:10 - 15:30	Feedback from workshop 3	
15:30 - 16:00	Discussion	
16:00 - 16:30	Wrap-up and action menu	Michael Watson
16:30	End of meeting	

